Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Stomach Neoplasms × Epirubicin × Clear all

Phase

Status

Completed 17 Terminated 6 Unknown 5 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 17 Triple Negative Breast Neoplasms 5 Stomach Neoplasms 1 Pathologic Complete Response 1 Neoplasms 1 Inflammatory Breast Neoplasms 1

Interventions

Oxaliplatin 22 pembrolizumab 19 Capecitabine 15 Nivolumab 13 Fluorouracil 12 Leucovorin 11 Paclitaxel 9 Trastuzumab 7 Docetaxel 7 atezolizumab 6 tislelizumab 4 durvalumab 4 Ramucirumab 4 Irinotecan 4 Cisplatin 4 Carboplatin 4 zolbetuximab 3 zimberelimab 3 olaparib 3 bemarituzumab 3 S 1 (combination) 3 Gemcitabine 3 Bevacizumab 3 tremelimumab 2 camrelizumab 2 apatinib 2 Taxes 2 Standard of Care 2 Radiotherapy 2 Radiosurgery 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01924819 2025-03-04

TOPGEAR

Australasian Gastro-Intestinal Trials Group

Phase 2/3 Active not recruiting

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡